Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 18, 2016

Interpace Diagnostics’ PancraGen test assigned new current procedural terminology code

US-based Interpace Diagnostics has announced its medicare administrative carrier (MAC), Novitas Solutions has assigned a new molecular current procedural terminology (CPT) code, 81479 to its PancraGen test.

Pancragen

US-based Interpace Diagnostics has announced its medicare administrative carrier (MAC), Novitas Solutions has assigned a new molecular current procedural terminology (CPT) code, 81479 to its PancraGen test.

Previously, the PancraGen test was covered under the miscellaneous chemistry code 84999, which is used to bill a range of tests across the laboratory industry and does not differentiate between technologies with different features.

Interpace Diagnostics interim CEO Jack Stover said: "The CPT coding change represents further confirmation from payers that PancraGen is a clinically comprehensive and robust molecular test that provides novel insights to physicians and patients dealing with this life altering disease.

"The CPT coding change represents further confirmation from payers that PancraGen is a clinically comprehensive and robust molecular test that provides novel insights to physicians and patients dealing with this life altering disease."

"The new coding enables both Interpace Diagnostics and those hospitals that bill Medicare directly to use a molecular code when billing for PancraGen, which could result in incremental reimbursement above the established Diagnosis-Related Group (DRG) payment for this condition."

The new code will have a positive impact on the way claims are submitted and remittances are received from both Medicare and commercial payers.

PancraGen is an integrated molecular pathology test to determine the risk of cancer in pancreatic cysts by using a small sample of a thick or viscous pancreatic cyst fluid.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

According to clinical studies, PancraGen is claimed to be 90% accurate, enabling effective risk stratification of patients.


Image: A diagnostic image of pancreatic pseudocyst. Photo: courtesy of James Heilman, MD / Wikipedia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU